Bone Biologics is on the brink of completing an important milestone in its mission to develop the NELL-1 osteoinductive protein into a commercially viable product for spine surgery, as the firm plans to start large animal studies in the second half of 2016.
Stephen La Neve, CEO of Bone Biologics, said the company is focused on using NELL-1 in “hard to heal” patients undergoing posterolateral fusions and transforaminal lumbar interbody fusions. The hard-to-heal group includes smokers, diabetics, the obese and those with osteoporosis. The company is optimistic NELL-1 will speed-up healing and improve the strength of fusion in these patients.
Read the full article: Bone Biologics Reaches Major Preclinical Milestone In Regenerative Bone Material Development (Clinica)
News
- Client News
